ACCL vs BIOX
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 03, 2026
ACCL
BIOX
Investment Advisor Scores
BIOX
AI Analyst Insights
Detailed Metrics Comparison
| Metric | ACCL | BIOX | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 14.9925 | Tie |
| PEG Ratio | 0 | 1.9521 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 1.0% | -35.9% | ACCL |
| Earnings Growth | -84.0% | 34.4% | BIOX |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 51.2/100 | 44.3/100 | ACCL |
| Profit Margin | 11.3% | -96.9% | ACCL |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
ACCL
MarkupPrice above SMA50, rising 50-day trend (14.5% over 20 days), RSI 78
BIOX
NeutralMixed signals - no dominant trend phase, RSI 59
Fundamentals Snapshot
| Metric | ACCL | BIOX |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 0.0 | 7.4 |
| Trailing P/E | 55.8 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | -0.4% |
| Gross Margin | 0.4% | 0.4% |
| Operating Margin | 0.0% | -0.2% |
| EPS | 0.04 | -1.06 |
| Dividend Yield | — | — |